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Simvastatin decreases the level of heparin-binding
protein in patients with acute lung injury
Daniel F McAuley1,2, Cecilia M O’Kane2, Thelma R Craig1, Murali Shyamsundar1, Heiko Herwald3 and Karim Dib2*
Abstract
Background: Heparin-binding protein is released by neutrophils during inflammation and disrupts the integrity of
the alveolar and capillary endothelial barrier implicated in the development of acute lung injury and systemic organ
failure. We sought to investigate whether oral administration of simvastatin to patients with acute lung injury
reduces plasma heparin-binding protein levels and improves intensive care unit outcome.
Methods: Blood samples were collected from patients with acute lung injury with 48 h of onset of acute lung
injury (day 0), day 3, and day 7. Patients were given placebo or 80 mg simvastatin for up to 14 days. Plasma
heparin-binding protein levels from patients with acute lung injury and healthy volunteers were measured by ELISA.
Results: Levels of plasma heparin-binding protein were significantly higher in patients with acute lung injury than
healthy volunteers on day 0 (p = 0.011). Simvastatin 80 mg administered enterally for 14 days reduced plasma level
of heparin-binding protein in patients. Reduced heparin-binding protein was associated with improved intensive
care unit survival.
Conclusions: A reduction in heparin-binding protein with simvastatin is a potential mechanism by which the statin
may modify outcome from acute lung injury.
Trial registration: Current controlled trials: ISRCTN70127774
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Background
Acute lung injury (ALI), and its most severe form, the
adult respiratory distress syndrome (ARDS) are inflam-
matory disorders which are commonly caused by the
systemic release of cytokines and pro-inflammatory mol-
ecules [1]. In the United States, there are approximately
190,000 cases per year of ALI with an associated death
of 74,500 per year [1]. ALI is characterized by alveolar
epithelial and capillary endothelial barrier damage, re-
sulting in exudation of protein-rich oedema fluid into
the alveolar space, which causes functional impairment
of the gas exchange [1]. Uncontrolled and excessive infil-
tration of inflammatory cells, in particular neutrophils
and macrophages, is a hallmark of ALI. Neutrophils are
the main contributor in the pathogenesis of ALI. Indeed,
there is a correlation between the number of neutrophils
in bronchoalveolar (BAL) fluid and the severity of lung
injury [2] and persistence of neutrophils is associated
with mortality [3]. Neutrophils contribute to lung tissue
destruction in ALI by producing tissue damaging agents
such as reactive oxygen species, and granule-derived
proteases [1].
In ALI, extravasation of neutrophils into the alveolar
space is associated with disruption of the endothelial
barrier. The mechanisms by which neutrophils induce
change in alveolar and capillary endothelial barrier per-
meability is not well known, but may involve, at least in
part, heparin-binding protein (HBP).
HBP, also known as CAP37/azurocidin, is a 28 kDa
protein belonging to the serprocidin subgroup of the
chymotrypsin-like proteases [4]. HBP is contained in
azurophilic granules and secretory vesicles of neutrophils
[5]. HBP is released upon fusion of azurophilic granules
and secretory vesicles with the plasma membrane. The
basal release of HBP is augmented upon β2 integrin-
dependent adhesion of neutrophils to the vascular
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endothelium during inflammation [4]. HBP is a multi-
functional protein of inflammation that is responsible
for a number of host response mechanisms to infection.
HBP exhibits antimicrobial activity [6], induces recruit-
ment of monocytes to the site of inflammation [7], and
augments macrophage phagocytosis [8]. Besides its
beneficial effects during the immune response, HBP is
also a potent inducer of endothelial hyperpermeability
[4]. For example, neutrophil degranulation and the asso-
ciated release of HBP, can be triggered by the binding of
fibrinogen-coated M protein of streptococcus pyogenes to
β2 integrins, which causes a toxic shock syndrome char-
acterized by plasma leakage and multi-organ failure [9].
Statins are inhibitors of hydroxyl-methylglutaryl coen-
zyme A reductase, the enzyme which catalyses the
second reaction in the mevalonate-dependent biosyn-
thesis pathway. Statins are being investigated as a poten-
tial therapy for ALI. Statins attenuate lung injury in vivo
in mice which have received aerosolized lipopolysacchar-
ide (LPS) [10] and attenuate vascular leak and inflam-
mation in murine inflammatory lung injury [11]. In
humans, oral intake of simvastatin for 4 days attenuates
the systemic inflammatory response to intravenous LPS
[12]. We have recently shown that simvastatin reduces
pulmonary inflammation in vivo in healthy volunteers
who have inhaled a low dose of LPS [13]. In this human
model of ALI, simvastatin reduced LPS-induced BAL
neutrophilia, tumour necrosis factor α, matrix metal-
loproteinases and C-reactive protein. In a recent ran-
domized, double-blind trial of 60 patients with ALI (the
HARP study), we showed that simvastatin induced mod-
est improvement in non-pulmonary organ dysfunction
[14]. The mechanisms by which simvastatin exerted its
protective effect in the small single centre HARP study
were unclear. We hypothesised that the levels of plasma
HBP were elevated in patients with ALI and that the
protective effects of simvastatin were mediated by re-
duced plasma HBP levels.
Methods
Study population
The ALI population used to carry out this study has
been previously described in detail [14]. This was a
single-centre, prospective, double-blind, randomized,
placebo-controlled clinical trial in which patients with
ALI were randomized to simvastatin 80 mg or placebo
(1:1) for up to 14 days.
Baseline patient demographics, severity of illness scores
were collected at baseline [14]. Briefly, 60 mechanically
ventilated patients with ALI admitted to the regional In-
tensive Care Unit (ICU) in the Royal Victoria Hospital,
Belfast, Northern Ireland, were recruited to the study. Five
healthy subjects were recruited by advertising to undergo
plasma sampling. Screening consisted of history, physical
examination, routine blood investigation, electrocardio-
gram and spirometry. Healthy subjects included 4 males
and one female. Mean baseline of FEV1 (L) and FVC (L)
were 4.2(0.5) and 5.2(0.75), respectively. The study was
approved by the local research ethics committee, and
written informed consent was obtained from the legal
representative of the patient or the healthy individuals.
The research was carried out in compliance with the
Helsinki Declaration.
Preparation of plasma samples
Blood was collected in lithium heparin tubes (Becton-
Dickinson, Plymouth, UK) and placed immediately on
ice until processed. Plasma sampling for patients with
ALI were performed at baseline, before study drug ad-
ministration, and on day 3 and 7 as described [14]. Total
cell count was determined using a haemocytometer.
Measurement of HBP levels
Concentrations of HBP in plasma were determined using
a validated ELISA as described [5].
Statistical analysis
Data are expressed as median (interquartile range). Data
were analyzed by unpaired t-test or Mann–Whitney U-test
as appropriate. Data were analyzed using GraphPadPrism
(version 4.02, GraphPad Software, San Diego, CA).
Results
HBP is increased in plasma at onset of ALI
HBP concentration in plasma in healthy volunteers and
patients with ALI were measured at enrollment. The
median value of plasma HBP levels was 12.8 ng/ml in
healthy subjects (n = 5) and 16.7 ng/ml in patients with
ALI (n = 47). This corresponds to a 30% increase of HBP
in patients with ALI (P = 0.011) (Figure 1).
HBP levels and Intensive Care Unit mortality
We tested whether levels of HBP correlated with ICU
mortality. To this end, we compared concentrations of
plasma HBP in ICU survivors and ICU non-survivors
at enrolment and after 3 and 7 days in ICU. At enrol-
ment, and day 3, there was no significant difference in
plasma HBP levels between ICU survivors (n = 21) and
non-survivors (n = 9) (Figure 2A & B). However, at day
7 after enrolment, patients with ALI who did not sur-
vive had a significantly higher level of plasma HBP in
comparison to ICU survivors (p = 0.013) (Figure 2C).
The fold change in plasma HBP levels at day 7 ver-
sus day 0 was significantly lower (p = 0.022) in ICU
survivors (n = 21) than in ICU non-survivors (n = 9)
(Figure 2D). Collectively, these results indicate that
ICU survival is associated with decreased plasma HBP
levels at day 7.
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Simvastatin reduces plasma HBP levels in patients with ALI
We tested whether simvastatin could modify plasma
HBP concentrations in patients with ALI. The level of
plasma HBP decreased significantly at day 7 in both
patients treated with placebo (n = 16, p = 0.009) or
simvastatin (n = 12, p = 0.004) (Figure 3A). We found
that the fold change of plasma HBP in patients with ALI
treated with simvastatin was significantly lower than in
placebo-treated patients (P = 0.04) (Figure 3B). This re-
sult indicates that a more pronounced reduction in
plasma HBP levels is observed in patients with ALI
treated with simvastatin.
We corrected the concentrations of plasma HBP for
the number of neutrophils in blood. When the con-
centration of HBP was normalized for neutrophil counts,
we found no significant decrease in HBP levels at days
3 and 7 after enrolment in placebo-treated patients
(Figure 3C). In contrast, and similarly to above (Figures
3A & B), there was a significant decrease (p = 0.004) in
HBP levels in patients treated with simvastatin at day 7
(Figure 3C). The fold change of HBP at day 7 versus day 0
in patients treated with simvastatin was significantly (p =
0.014) lower than in placebo-treated patients (Figure 3D).
Discussion
Statins may have a beneficial role in ALI. We have re-
cently shown that oral administration of 80 mg simva-
statin to patients with ALI reduced pulmonary and
systemic inflammation [14]. Simvastatin improved sys-
temic organ failure with a trend to improvement in re-
spiratory dysfunction [14]. Multi-organ dysfunction is
caused, at least in part, by increased endothelial perme-
ability and simvastatin has been shown to improve lung
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Figure 1 Plasma levels of HBP in healthy individuals and
patients with ALI. Plasma samples were prepared from healthy
controls and patients with ALI immediately after 48 h recruitment to
ICU. Levels of plasma HBP were determined using a validated ELISA.
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Figure 2 ICU non-survivors have augmented plasma HBP level than ICU survivors. Plasma HBP levels at day 0 (A), day 3 (B), or day 7 (C) in
ICU survivors and ICU non-survivors are represented. (D) The fold change of HBP level at day 7 versus day 0 is represented in ICU survivors and
ICU non-survivors.
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permeability in endotoxin-induced ALI in mice [15]. As
HBP derived from neutrophils disrupts endothelial in-
tegrity causing vascular leakage and organ failure [4,9],
we aimed to investigate the levels of plasma HBP in pa-
tients with ALI and if simvastatin modified those levels.
As neutrophils play a central part in the pathogenesis of
ALI [1], we hypothesised that HBP concentrations in
plasma would be increased in patients with ALI. We
found that plasma HBP levels in patients with ALI were
significantly increased compared to healthy individuals.
Other investigators found elevated levels of plasma HBP
in patients with severe sepsis and septic shock [16,17]
and HBP concentrations higher or equal to 15 ng/ml
were found in 87% of critically ill patients with sepsis.
Furthermore, when plasma HBP levels reached this
threshold, there was a 4-fold increase of the mortality
rate among patients with sepsis [16].
We next investigated whether plasma HBP level was
associated with mortality. We found that plasma HBP
levels at enrolment were not significantly different be-
tween patients with ALI surviving ICU admission or
not. In contrast, other investigators found elevated HBP
levels at admission in other diseases including sepsis,
and this was associated with an increased mortality at 28
days [16]. We also observed that HBP levels decreased
significantly at day 7 versus day 0 in ICU survivors but
not in ICU non-survivors. Based on these findings, we
propose that normalization of plasma HBP level over the
time, rather than the concentration of HBP at enrol-
ment, is associated with recovery. It is plausible that
Figure 3 Simvastatin decreases the level of plasma HBP in patients with ALI. (A) Patients with ALI received either placebo or 80 mg
simvastatin. Thereafter, plasma samples were collected at day 3 and day 7, and the levels of HBP were measured by ELISA. Baseline plasma HBP
levels were measured before drug administration (day 0). (B) The fold change of HBP at day 7 versus day 0 was expressed for patients who have
received placebo or 80 mg simvastatin. (C) The data in (A) were corrected to neutrophil counts. (D) The fold change of HBP corrected for
neutrophil counts at day 7 versus day 0 was expressed for patients who have received placebo or 80 mg simvastatin.
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strategies to decrease plasma HBP levels may reduce
endothelial leak and may be a potential therapeutic strat-
egy to further investigate.
Simvastatin reduces pulmonary and systemic inflam-
mation in patients with ALI [14] and in a human model
of ALI induced by inhaled LPS [13]. Therefore, we inves-
tigated whether simvastatin reduced plasma HBP levels
in patients with ALI. We found that patients treated
with simvastatin had a greater fold reduction in plasma
HBP levels at day 7 versus day 0 than those who re-
ceived placebo. This relation persisted when corrected
for neutrophil count suggesting this is not simply a re-
flect of reduced peripheral neutrophil counts but re-
duced neutrophil activation.
The relatively small sample size used in this study
limits the interpretation of the data. Although we found
that decreased plasma HBP levels was associated with
survival and simvastatin decreased plasma levels of HBP
in patients with ALI, simvastatin did not improve ALI
survival [14]. It would be necessary to conduct a larger
study in patients with ALI to confirm the association be-
tween the administration of simvastatin, reduced plasma
levels of HBP, and survival which is ongoing [18].
Pro-inflammatory cytokines and chemokines, which
characterise ALI, induce expression of β2 integrins (LFA-1
and Mac-1) on the membrane surface of neutrophils [19]
and switch these adhesion receptors from a low to a high
affinity ligand binding conformation [20]. This change in
conformation allows the β2 integrins to bind endothelial
ligands, which is a prerequisite for extravasation and acti-
vation of neutrophil inflammatory functions including
degranulation (and release of HBP). Interestingly, statins
have been shown to bind to an allosteric site within the β2
integrin LFA-1 which prevents LFA-1 interacting with
endothelial ligands. This has been shown to impair migra-
tion of neutrophils in a murine peritonitis model [21].
Although statins do not bind Mac-1 [21], the dominant
β2 integrin expressed in neutrophils, simvastatin has
been shown to reduce expression of Mac-1 on the
membrane surface of circulating neutrophils by redu-
cing the level of pulmonary CXC chemokines [22]. Ac-
cordingly, potential mechanism for our finding is that
simvastatin blocks β2 integrin-dependent release of
HBP and other granule proteins.
Conclusions
This study has shown that the concentration of HBP in
plasma was increased in patients with ALI compared to
healthy individuals. Furthermore, we found that at day 7
after onset of ALI, high plasma HBP levels was associated
with mortality. Simvastatin was associated with greater re-
duction in plasma HBP. A greater reduction in plasma
HBP may be one of the mechanism by which simvastatin
exerts a potential protective effect.
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